<code id='ABAB687A06'></code><style id='ABAB687A06'></style>
    • <acronym id='ABAB687A06'></acronym>
      <center id='ABAB687A06'><center id='ABAB687A06'><tfoot id='ABAB687A06'></tfoot></center><abbr id='ABAB687A06'><dir id='ABAB687A06'><tfoot id='ABAB687A06'></tfoot><noframes id='ABAB687A06'>

    • <optgroup id='ABAB687A06'><strike id='ABAB687A06'><sup id='ABAB687A06'></sup></strike><code id='ABAB687A06'></code></optgroup>
        1. <b id='ABAB687A06'><label id='ABAB687A06'><select id='ABAB687A06'><dt id='ABAB687A06'><span id='ABAB687A06'></span></dt></select></label></b><u id='ABAB687A06'></u>
          <i id='ABAB687A06'><strike id='ABAB687A06'><tt id='ABAB687A06'><pre id='ABAB687A06'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:hotspot    - browse:189
          Adam's take main illustration
          Molly Ferguson/STAT

          Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

          Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

          advertisement

          Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot